Amanta Healthcare IPO Overview
Amanta Healthcare Ltd. IPO opens September 1, 2025, and closes September 3, 2025. The fresh issue comprises 1 crore equity shares (₹10 face value), raising ₹126 crore via a book-building process. The issue price band is ₹120–126 per share. Proceeds will fund two new manufacturing lines—₹70 crore for SteriPort and ₹30.13 crore for SVP—plus general corporate purposes. Tentative listing is scheduled for September 8–9 on BSE and NSE.
Amanta Healthcare Subscription and GMP Status
| Subscription Rate Source: NSE/BSE | |||
| Category | Shares Offered | Shares Bid For | Subscription (x) |
| QIBs | 20,00,000 | 7,17,22,490 | 35.86 |
| NIIs | 15,00,000 | 31,40,04,705 | 209.34 |
| Retails | 35,00,000 | 19,15,70,484 | 54.73 |
| Employees | |||
| Shareholders | |||
| Total | 70,00,000 | 57,72,97,679 | 82.47 |
| Last Updated: 03 Sep 2025 5 PM | |||
| GMP (₹) (grey market premium) | IPO Price (₹) |
| 8.5 | 120-126 |
| Last Updated: 03 Sep 2025 5 PM | |
| 📌 Note: The above GMP data is unofficial and has been collected from multiple sources including grey market dealers and market observers. It is provided purely for informational and educational purposes. Please consult your financial advisor before making any investment decisions. | |
IPO Key Date
Core Business & Overview
Amanta Healthcare Ltd, incorporated in December 1994, is an Indian pharmaceutical company specializing in the development, manufacturing, and marketing of sterile liquid products, particularly parenteral formulations. They utilize advanced packaging technologies such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) for both large-volume parenterals (LVPs) and small-volume parenterals (SVPs), along with a diverse offering of medical devices.
Their product range spans six therapeutic segments:
- Fluid therapy (IV fluids),
- Formulations,
- Diluents,
- Ophthalmic solutions,
- Respiratory care,
- Irrigation solutions.
They also produce medical devices including eye lubricants and first-aid products.
Manufacturing & Distribution Capabilities
- The company operates a single WHO-GMP and ISO-certified facility in Hariyala, Kheda district, Gujarat, India, covering around 66,852 sq m, equipped with multiple production lines (e.g., two conventional ABFS lines and two SteriPort ISBM lines for LVPs, along with SVP lines).
- They boast a wide domestic marketing network, with over 316–320 distributors and a sales team of approximately 96–108 members catering to hospitals and nursing homes.
- On the international front, they have product registrations in up to 120 jurisdictions and exports to 19–21 countries, spanning both regulated and semi-regulated markets.
Strengths
- Broad & Diversified Product Portfolio
Spread across six therapeutic segments with a range of closure systems (e.g., nipple head, twist-off, leur-lock, screw) and fill volumes (2 ml to 1000 ml), enabling demand resilience. - Robust Manufacturing Infrastructure & Tech Capability
Large-scale facility with advanced ABFS and ISBM technologies, enabling flexible, efficient production. - Strong Distribution & Marketing Network
Extensive domestic reach through hundreds of distributors and a sizeable salesforce, enhancing market penetration. - International Footprint
Registered products in many jurisdictions, with exports contributing over 30% of revenue in FY25; offers geographical diversification. - Experienced Leadership & Workforce
Promoted by industry veterans (Patel family and Milcent Appliances) with decades of pharma experience. As of March 31, 2025, the company employed over 1,700 staff across development, manufacturing, and quality labs. - Favorable Industry Tailwinds
Growth in India’s injectables and IV fluids markets is expected (CAGR 7–11%) through 2029. Amanta’s specialized manufacturing capabilities and regulatory accreditations position them well to capitalize.
Risks
- Single-Facility Production Risk
Complete reliance on one plant in Hariyala exposes the company to severe operational risks (e.g., power/water outages, machinery breakdowns, natural disasters). - Raw Material & Supply Dependency
Dependence on limited suppliers for LDPE/PP granules ties profitability to crude-oil linked raw material price volatility. - Legal and Regulatory Exposure
The company faces material litigation; unfavorable outcomes could have substantial financial or reputational impacts. Past manufacturing license suspension underscores regulatory vulnerability. - Customer Concentration Risk
The top 10 clients accounted for roughly 28–31% of total revenue in recent years (FY23–FY25). Losing any major client could hurt revenues. - Export-Related Risks
Exposure to exchange fluctuations, differing regulatory environments, and tariffs could adversely impact profitability and operations. - Workforce Attrition
High employee turnover: 33.8% in FY23, 25.9% FY24, although improved to 9.9% in FY25. Still, workforce disruption may affect continuity. - Contingent Liabilities & Debt Burden
FY25 contingent liabilities stood at ₹11.6 cr, and total indebtedness was ₹194.5 cr, with failure to service or legal realization could strain finances.
Financial Performance Overview (₹ in Crore)
| Year | Revenue | Profit | Assets |
| FY 2023 | 259.13 | -2.11 | 374.06 |
| FY 2024 | 280.34 | 3.63 | 352.12 |
| FY 2025 | 274.71 | 10.50 | 381.76 |
Revenue:
The company’s revenue increased from ₹259.13 Cr in FY 2023 to ₹280.34 Cr in FY 2024, but slightly dipped to ₹274.71 Cr in FY 2025. This shows moderate fluctuations, indicating some inconsistency in sales growth.
Profit:
The company turned profitable after a loss in FY 2023 (₹-2.11 Cr). Profits rose significantly to ₹10.5 Cr in FY 2025, showing strong operational improvement and cost control.
Assets:
Assets declined in FY 2024 but bounced back strongly in FY 2025 to ₹381.76 Cr, reflecting renewed investment and stronger financial positioning.
Disclaimer:
The above IPO analysis and financial data are based on information provided by the company in its official documents. For complete details, please refer to the Red Herring Prospectus (RHP) linked above. Investors are strongly advised to consult their financial advisor before making any investment decisions.
